GlaxoSmithKline's malaria vaccine, RTS,S or Mosquirix, has won a positive opinion from the EMA's Committee for Medicinal Products for Human Use for use in children aged 6 weeks to 17 months outside the European Union, the agency said in a statement.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
Just days ago, GlaxoSmithKline signed the first big deal with the Francis Crick Institute. And now a high-profile examination of the state of play of partnering in academic research circles, the Dowling Report, says Glaxo is the single largest collaborator with academia in the U.K., for any industry.
Early signs of the upcoming flu season came this week as three vaccine makers--GlaxoSmithKline, Sanofi Pasteur and bioCSL--announced their first shipments of flu shots for the 2015-16 season, with two reporting that they will increase the amount of doses they deliver.
Final trial results reported in April showed that the efficacy of GlaxoSmithKline's investigational malaria vaccine wanes over time. But the candidate, dubbed RTS,S or Mosquirix, is the furthest along in the quest for a vaccine and so, may win WHO and EMA approval as the first vaccine against malaria.
Autifony Therapeutics has returned to its investors for £8 million ($12 million) to fund a broadening of its R&D ambitions. The company, which spun out of GlaxoSmithKline with an age-related hearing loss program in 2011, is now going after schizophrenia.
Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.
Although the waning Ebola outbreak had Big Pharmas struggling to find volunteers for their Ebola vaccine trials, two new Phase II trials are going forward. GlaxoSmithKline will take its candidate to Senegal, while Johnson & Johnson and partner Bavarian Nordic will test their vaccine in France and the U.K.
The newly consolidated GSK Consumer Healthcare business is in turn consolidating its media planning and buying. Group M's Mediacom and Omnicom Media Group's PHD, two of the largest global media agencies that are already on the roster for GSK, are in the final bid for the estimated $900 million account.
GlaxoSmithKline is the first pharma company to get behind the U.K.'s forthcoming Francis Crick Institute, signing on to lend its minds and molecules to an open R&D effort.